CRISPR/Cas9-based liver-derived reporter cells for screening of mPGES-1 inhibitors

6Citations
Citations of this article
11Readers
Mendeley users who have this article in their library.
Get full text

Abstract

mPGES-1 is a terminal rate-limiting enzyme responsible for inflammation-induced PGE2 production. The inhibition of mPGES-1 has been considered as a safe and effective target for the treatment of inflammation and cancer. However, a specific, efficient, and simple method for high-throughput screening of mPGES-1 inhibitors is still lacking. In this study, we developed a fluorescence imaging strategy to monitor the expression of mPGES-1 via CRISPR/Cas9 knock-in system. Immunofluorescence colocalisation, Sanger sequencing, RNAi, and IL-1β treatment all confirmed the successful construction of mPGES-1 reporter cells. The fluorescence signal intensity of the reporter cells treated with four conventional mPGES-1 inhibitors was considerably attenuated via flow cytometry and fluorescent microplate reader, demonstrating that the reporter cells can be used as an efficient and convenient means for screening and optimising mPGES-1 inhibitors. Moreover, it provides a new technical support for the development of targeted small molecule compounds for anti-inflammatory and tumour therapy.

Cite

CITATION STYLE

APA

Chen, Z., Cai, X., Li, M., Yan, L. L., Wu, L., Wang, X., & Tang, N. (2019). CRISPR/Cas9-based liver-derived reporter cells for screening of mPGES-1 inhibitors. Journal of Enzyme Inhibition and Medicinal Chemistry, 34(1), 799–807. https://doi.org/10.1080/14756366.2019.1587416

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free